Podcasts > Archived Podcasts > Industry Focus
This show is no longer producing new episodes. Check out our other shows.
Industry Focus
Healthcare: Mylan's Big Bet
Oct 11, 2017 (18:30)
Mylan launches a generic "at-risk" and Flexion's big drug opportunity becomes clearer.
Editor's note: Mylan's drug was mistakenly referred to in the episode as a biosimilar. Copaxone, however, was approved under an NDA, not a BLA, so Mylan's copycat is a generic, not a biosimilar.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.